Aeluma heads into its fiscal first-quarter report with a story that has outrun its numbers. Last quarter management laid out an aggressive pivot toward AI data center photonics, backed by a fatter cash balance, a doubled engineering team and a $30 million CHIPS letter of intent. Yet revenue barely registered, losses widened and the company declined to give full-year guidance. The market has sided with the skeptics, and this report is the first real chance for Aeluma to show that its commercial pipeline is turning into signed agreements rather than just conversations.

The Street expects a loss of 13 cents a share on revenue of roughly $500,000, a 64% drop from the $1.4 million posted a year ago and a touch below the $582,000 reported last quarter. The year-ago loss was just 3 cents, so this is a quarter of clear contraction on both lines. One wrinkle stands out: consensus is modeling a narrower loss than the 22 cents Aeluma lost last quarter, even though headcount has climbed past 30 and adjusted EBITDA slid to a negative $2.9 million in the fourth quarter. With management guiding to $10 million to $12 million of capital spending this fiscal year for new Aixtron MOCVD reactors and tools, operating costs are more likely to rise than fall. A loss meaningfully wider than 13 cents would not be shocking, and the size of any gap matters less than whether spending is buying visible commercial progress.

There is no formal guidance to measure against. Management offered only about $2.3 million of booked government revenue for the year plus roughly $2 million of possible upside, after a guidance history that slipped from $4 million to $6 million down to $4.2 million to $4.6 million. That progression makes credibility a central issue. The most important evidence would be conversion of the several multi-million-dollar nonrecurring engineering agreements management said it was negotiating with top-tier customers. A signed NRE deal with a recognizable AI datacom name would validate the pivot far more than any revenue figure this quarter. Continued talk of negotiations without closings would suggest the commercial timeline is stretching, just as government contract revenue is being deliberately de-emphasized.

Several other threads need updates. The CHIPS award remains an unsigned letter of intent, likely structured as government equity rather than revenue, so progress toward a definitive agreement would ease dilution worries. Investors should also look for clarity on the timing of the Sumitomo Chemical capacity expansion and MOCVD deliveries, given that management framed indium phosphide shortages as a demand tailwind. The Navy photodetector program's move to phase two offers a modest but tangible proof point on speed and transceiver integration. Finally, burn rate deserves scrutiny. The $56 million cash balance was built partly through an at-the-market raise at nearly $25 a share; with the stock now around $7, further equity issuance would be far more dilutive.

That price collapse frames the setup. Shares have fallen 35% since the last report while the S&P 500 was roughly flat, and at $7.26 the stock sits well under its 200-day moving average of $16.47 and only about 10% above its post-earnings low of $6.59. The prior quarter's trading range of $12.25 to $28.79 now looks like a different era. Sentiment leans bearish, with about 56% of respondents negative. Expectations, in short, are already depressed, which lowers the bar for a relief move but also signals deep doubt about execution.

The central question is simple. Revenue this quarter is almost beside the point; Aeluma needs to show that its AI datacom ambitions are producing signed commercial contracts and a finalized CHIPS agreement while keeping cash burn under control. Delivering that would restore some faith in the narrative. Another quarter of rising costs and unsigned deals would leave the stock priced as an expensive science project.